August 12, 2024
(press release)
–
Fujifilm Holdings Corporation
announced today the financial results for the first quarter, which ended
June 30, 2024
.
In the first three months of the fiscal year ending
March 2025
, revenue increased by 13.4% year-over-year to
JPY749.0 billion
, mainly due to strong sales in the Electronics, Imaging and Medical Systems businesses, and the favorable impact of exchange rates. Operating income also benefited from the revenue growth and exchange rate impact, amounting to
JPY62.2 billion
, increased by 19.1% year-over-year. Net income attributable to
Fujifilm Holdings
increased by 11.6% year-over-year to
JPY60.7 billion
. In light of the strong performance of the Electronics and Imaging segment and the exchange rate, full-year consolidated forecast for the fiscal year ending
March 2025
revised upward, at revenue of
JPY3150.0 billion
, operating income of
JPY315.0 billion
, and net income attributable to
Fujifilm Holdings
of
JPY250.0 billion
, aimed to achieve its record highs. The annual dividend forecast for the fiscal year is
JPY60
per share, marking the 15th consecutive annual dividend increase.
“We achieved exceptional milestones in the first quarter of fiscal year 2024, primarily driven by the outstanding performance of the Electronics and Imaging businesses,” says
Teiichi Goto
, president and chief executive officer, representative director,
Fujifilm Holdings Corporation
. “This quarter saw our highest ever sales, operating income, and net income again. We are pleased that we have made a strong start toward achieving the goals of our mid-term management plan, VISION2030.”
Highlights by business segments
Healthcare:
* Revenue increased 10.8% year-over-year to
JPY229.2 billion
due to higher contributions from Medical Systems and Bio CDMO businesses, while operating income decreased 67.1% year-over-year to
JPY3.4 billion
mainly attributed to structural reform expenses for Bio CDMO’s small and medium-sized facilities and expenses aimed at expanding the capacity of commercial production at the
Texas
site in the
U.S.
* In the Medical Systems business, revenue was driven higher by steady sales of endoscopes, CT, MRI and other products.
* In the Bio CDMO business, revenue increased due to the solid performance in contract manufacturing of antibody drugs, mainly at the
Denmark
site. Meanwhile, in small- and medium-sized manufacturing facilities affected by market stagnation, leading to planned structural reforms being implemented in Q1 2024 for rebuilding the production system based on demand conditions. In addition, in order to accommodate the expected increase in demand for the contract manufacturing of commercial products, operations of the small and medium-sized manufacturing facilities at the
Texas
site in the
U.S.
were temporarily suspended, for implementing system upgrades to achieve stable production and to strengthen the quality assurance system to improve regulatory compliance. As a result, losses from non-operation of facilities and corresponding expenses were recorded.
* In the LS Solutions business, while Life Sciences remained flat, dietary supplement sales in the
Consumer Healthcare
declined as the overall supplement market stagnated in
Japan
.
Electronics:
* Revenue increased 37.9% year-over-year to
JPY109.1 billion
and operating income increased 105.8% year-over-year to
JPY20.1 billion
, mainly attributed to the market recovery in semiconductor materials and contribution from revenue of acquired semiconductor process chemicals, as well as strong sales of materials for OLEDs in the Advanced Functional Materials business.
* In the Electronic Materials business, revenue increased 53.6% year-over-year due to the market recovery in semiconductor materials and contribution from revenue of acquired semiconductor process chemicals.
* In the Advanced Functional Materials business, revenue increased 21.4% year-over-year as favorable orders, particularly for antireflection materials for OLEDs.
Business innovation:
* Overall revenue increased by 3.9% year-over-year to
JPY280.0 billion
, but operating income decreased by 12.9% year-over-year to
JPY14.4 billion
, due to the impact of new product development expenses and increased labor costs.
* In the Business Solutions business, revenue increased mainly due to higher sales of solutions related to digital transformation (DX).
* In the
Office Solutions
business, revenue rose as the increased exports of consumables to
Europe
and the
U.S.
, where inventory adjustments have progressed.
* In the
Graphic Communications
business, revenue increased due to increased sales of printing plates for the
U.S.
, digital printers for
Europe
and the
U.S.
, and inkjet heads for the ceramic and commercial printing markets.
Imaging:
* Strong sales of instant photo systems and digital cameras boosted revenue by 24.2% year-over-year to
JPY105.2 billion
and operating income by 38.9% year-over-year to
JPY32.5 billion
.
* In the Consumer Imaging business, steady sales of the “instax™” instant photo systems drove revenue higher.
* In the Professional Imaging business, revenue rose due to strong sales of digital cameras released in the previous fiscal year.
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistribute or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.